Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1269
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1081–1092 of 1,269 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT03794349
Site status not listed — check the official record
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions
Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
124
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Recruiting Phase 2 Interventional

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

NCT06517641
Status at this site: Recruiting
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Recruiting Not applicable Interventional

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

NCT05758545
Status at this site: Recruiting
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
COMS One device, Sham device
Device
Lead sponsor
Piomic Medical
Industry
Eligibility
22 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Castro Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Recruiting Not applicable Interventional

AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

NCT06939803
Status at this site: Recruiting
View directory record Official record
Conditions
Venothromboembolism
Interventions
Risk model-driven CDS
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
2,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Active, not recruiting Not applicable Interventional Results available

Eliminating Monitor Overuse Trial (EMO Trial)

NCT05132322
Site status not listed — check the official record
View directory record Official record
Conditions
Bronchiolitis Acute Viral
Interventions
Educational Outreach, Audit & Feedback (unit level), Audit & Feedback (real time, individual-level), Clinical Pathway Integrated into Electronic Health Record
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months and older
Enrollment
9,265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Davis, California • Encinitas, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The CONFORMAL Early Feasibility Study

NCT03616028
Site status not listed — check the official record
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
left atrial appendage closure
Device
Lead sponsor
Conformal Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Manchester, New Hampshire + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Recruiting Phase 1 Interventional

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

NCT04903119
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Melanoma, BRAF Gene Mutation
Interventions
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib, Encorafenib, Binimetinib
Drug
Lead sponsor
Rina Plattner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Recruiting Phase 1 Interventional

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions
CLSP-1025
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Active, not recruiting No phase listed Observational

Epidemiology of Silent and Overt Strokes in Sickle Cell Disease

NCT03376893
Site status not listed — check the official record
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickle Cell Disease, Stroke, Sickle Cell Thalassemia, Sickle Cell-Beta0-Thalassemia
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Recruiting Phase 3 Interventional

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

NCT04378790
Status at this site: Recruiting
View directory record Official record
Conditions
Amblyopia
Interventions
Patching, Glasses
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 13 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
68
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 9, 2026, 5:35 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241
Site status not listed — check the official record
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 9, 2026, 5:35 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.